India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?
Executive Summary
India plans pivotal tweaks to its three-layered review process for clinical trial-related clearances – a move that is expected to pare approval timelines significantly and improve predictability for sponsors who have been generally cautious, over the recent past, about placing studies in the country.
You may also be interested in...
Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India
Novartis’s plans for triple drug diabetes combination which includes vildagliptin have been turned down in India at least for now, with an expert panel questioning the rationale of such therapy.
No Trial Waiver Sail-Through For Lilly’s Taltz In India?
Eli Lilly's Taltz (ixekizumab) may be staring at stretched launch timelines in India where competitor secukinumab already has a head start, after the US company's request for a local trial waiver for the product was turned down twice.
AstraZeneca's Imfinzi, Lynparza On Track To India Debut
AstraZeneca, which recently committed to scaling up investments in India, appears on course to bringing two key new anticancers to the country, including the PD-1/L1 inhibitor Imfinzi. Pricing aspects for the products in what is a largely out-of-pocket market are, however, expected to be decisive.